🎉 M&A multiples are live!
Check it out!

Precision BioSciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Precision BioSciences and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Precision BioSciences Overview

About Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.


Founded

2006

HQ

United States of America
Employees

108

Financials

LTM Revenue $54.0M

LTM EBITDA -$28.0M

EV

-$9.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Precision BioSciences Financials

Precision BioSciences has a last 12-month revenue of $54.0M and a last 12-month EBITDA of -$28.0M.

In the most recent fiscal year, Precision BioSciences achieved revenue of $68.7M and an EBITDA of $13.5M.

Precision BioSciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Precision BioSciences valuation multiples based on analyst estimates

Precision BioSciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $48.7M $68.7M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$32.0M $13.5M XXX XXX XXX
EBITDA Margin -66% 20% XXX XXX XXX
Net Profit -$112M -$61.3M XXX XXX XXX
Net Margin -229% -89% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Precision BioSciences Stock Performance

As of April 15, 2025, Precision BioSciences's stock price is $4.

Precision BioSciences has current market cap of $46.7M, and EV of -$9.5M.

See Precision BioSciences trading valuation data

Precision BioSciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$9.5M $46.7M XXX XXX XXX XXX $-1.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Precision BioSciences Valuation Multiples

As of April 15, 2025, Precision BioSciences has market cap of $46.7M and EV of -$9.5M.

Precision BioSciences's trades at -0.2x LTM EV/Revenue multiple, and 0.3x LTM EBITDA.

Analysts estimate Precision BioSciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Precision BioSciences and 10K+ public comps

Precision BioSciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$9.5M XXX XXX XXX
EV/Revenue -0.1x XXX XXX XXX
EV/EBITDA -0.7x XXX XXX XXX
P/E 6.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Precision BioSciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Precision BioSciences Valuation Multiples

Precision BioSciences's NTM/LTM revenue growth is -65%

Precision BioSciences's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Precision BioSciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Precision BioSciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Precision BioSciences and other 10K+ public comps

Precision BioSciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 41% XXX XXX XXX XXX
EBITDA Margin 20% XXX XXX XXX XXX
EBITDA Growth -142% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -45% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 51% XXX XXX XXX XXX
R&D Expenses to Revenue 87% XXX XXX XXX XXX
Opex to Revenue 138% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Precision BioSciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Precision BioSciences M&A and Investment Activity

Precision BioSciences acquired  XXX companies to date.

Last acquisition by Precision BioSciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Precision BioSciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Precision BioSciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Precision BioSciences

When was Precision BioSciences founded? Precision BioSciences was founded in 2006.
Where is Precision BioSciences headquartered? Precision BioSciences is headquartered in United States of America.
How many employees does Precision BioSciences have? As of today, Precision BioSciences has 108 employees.
Who is the CEO of Precision BioSciences? Precision BioSciences's CEO is Mr. Michael Amoroso.
Is Precision BioSciences publicy listed? Yes, Precision BioSciences is a public company listed on NAS.
What is the stock symbol of Precision BioSciences? Precision BioSciences trades under DTIL ticker.
When did Precision BioSciences go public? Precision BioSciences went public in 2019.
Who are competitors of Precision BioSciences? Similar companies to Precision BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Precision BioSciences? Precision BioSciences's current market cap is $46.7M
What is the current revenue of Precision BioSciences? Precision BioSciences's last 12-month revenue is $54.0M.
What is the current EBITDA of Precision BioSciences? Precision BioSciences's last 12-month EBITDA is -$28.0M.
What is the current EV/Revenue multiple of Precision BioSciences? Current revenue multiple of Precision BioSciences is -0.2x.
What is the current EV/EBITDA multiple of Precision BioSciences? Current EBITDA multiple of Precision BioSciences is 0.3x.
What is the current revenue growth of Precision BioSciences? Precision BioSciences revenue growth between 2023 and 2024 was 41%.
Is Precision BioSciences profitable? Yes, Precision BioSciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.